Day One Bio Day One Bio

Scientific Publications

Contributing to and advancing the scientific dialogue.

June 2023

Clinical activity of pan-RAF inhibitor tovorafenib in the registrational pediatric low-grade glioma arm of the phase 2 FIREFL Y-1 (PNOC026) study

Lindsay Kilburn, Dong-Anh Khuong-Quang, Karsten Nysom, Daniel Landi, David S. Ziegler, Pablo Hernaiz Driever, Sarah Leary, Simon Bailey, Jasper Van der Lugt, Sebastien Perreault, Angela J. Waanders, Patricia Baxter, Olaf Witt, Darren Hargrave, Geoffrey McCowage, Xin Zhao, Daniel Da Costa, Michael C. Cox, Peter Manley, Jordan R. Hansford 2023 ASCO Annual Meeting, June 2-6, 2023, Chicago, IL & Online. Abstract number 10004

June 2023

LOGGIC/FIREFLY-2: A phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration

Cornelis M. van Tilburg, Lindsay Kilburn, Erin Crotty, Amy A. Smith, Sebastien Perreault, Andrea T. Franson, Nada Jabado, Lindsey M. Hoffman, Rene Schmidt, Antoinette Y.N. Schoutenvan Meeteren, Astrid Sehested, Enrico Opocher, Pablo Hernáiz Driever, Shivaram Avula, David S. Ziegler, Jiaheng Qiu, Li-Pen Tsao, Peter Manley, Darren Hargrave, Olaf Witt ASCO Annual Meeting 2023: Abstract TPS10067

June 2023

Healthcare resource use for pediatric low-grade glioma care: a cohort of linked electronic health records and claims data

Tabitha Cooney, Sandie Yu, Shailaja Daral, Michelle A Field, Blake Krebs, Mark Kieran, Peter Manley, Sandya Govinda Raju, Susan Zelt 2023 ASCO Annual Meeting: Abstract 10038

May 2023

Phase 1 study of the pan RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma

Rasco DW, Medina T, Corrie P, Pavlick AC, Middleton MR, Lorigan P, Hebert C, Plummer R, Larkin J, Agarwala SS, Daud AI, Qiu J, Bozon V, Kneissl M, Barry E, Olszanski AJ. [published online ahead of print May 23, 2023]. Cancer Chemother Pharmacol. 2023;92:15-28.

May 2023

Chart audit in pediatric low-grade glioma: molecular testing and treatment patterns

David Lee, Jorge Caravia, Kevin Lam, Judith Kulich, Katie Blodget, Sandya Govinda Raju 2023 ASPHO Conference: Poster 261

May 2023

pLGG disease burden and healthcare utilization: linked claims and EHR data study

Tabitha Cooney, Sandie Yu, Shailaja Daral, Blake Krebs, Riddhi Markan, Michelle A Field, Mark Kieran, Sandya Govinda Raju, Susan Zelt 2023 ASPHO Conference: Poster 258

April 2023

Clinical activity of the type II pan-RAF inhibitor tovorafenib in BRAF-fusion melanoma

Jeeyun Lee, MD, Natraj R. Ammakkanavar, MD, Aprajita Saini, MS, Mark W. Kieran MD, PhD, Lisa M. Kopp, DO, MPH, Bert H. O’Neil, MD 19th EADO Congress 2023: Paper #174

November 2022

FIREFLY-1 (PNOC026): Phase 2 study of pan-RAF inhibitor tovorafenib in pediatric and young adult patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors

Kilburn L, Landi D, Leary S, Ziegler DS, Baxter P, Franson A, McCowage G, Waanders AJ, Van der Lugt J, Oren MY, Gerber NU, Gottardo NG, Khuong-Quang D-A, Nysom K, Bailey S, Hernáiz Driever S, Perreault S, Witt O, Hahn S, Hargrave D, Hassall T, Jabado N,Kang HJ, Larouche V, Toledano H, Kline C, Abdelbaki MS, Chi SN, Gardner SL, Whipple N, Mueller S, Blackman, SC, Zhao X, Da Costa D, Cox MC, Packer R, Hansford JR 2022 Society for Neuro-Oncology – Annual Meeting 2022 SNO Annual Meeting: Abstract CTNI-68

See our progress in motion.

See open jobs

You are now leaving the Day One Biopharmaceuticals Corporate Website

You will now be redirected to the requested website. Please confirm that you want to proceed.

Yes No